Future studies should investigate whether the administration of a P2Y11 inhibitor or disruptor of the AKAP/P2Y11 or P2Y11/AC5 interface can prevent/ameliorate altered vascular reactivity and vascular complications in diabetes. Here, ADCY5 is linked to diabetes mellitus.